Bone Marrow Derived-mesenchymal Stem Cells Downregulate IL17A Dependent IL6/STAT3 Signaling Pathway in CCl4-induced Rat Liver Fibrosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Oct 23

PMID 30346985

Citations 19

Authors

Shimaa Farouk

Salwa Sabet

Fatma A Abu Zahra

Akmal A El-Ghor

Affiliations

Soon will be listed here.

Abstract

Therapeutic potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) has been reported in several animal models of liver fibrosis. Interleukin (IL) 17A, IL6 and Stat3 have been described to play crucial roles in chronic liver injury. However, the modulatory effect of MSCs on these markers was controversial in different diseases. BM-MSCs might activate the IL6/STAT3 signaling pathway and promote cell invasion in hepatocellular carcinoma, but the immunomodulatory role of BM-MSCs on IL17A/IL6/STAT3 was not fully elucidated in liver fibrosis. In the present study, we evaluated the capacity of the BM-MSCs in the modulation of cytokines milieu and signal transducers, based on unique inflammatory genes Il17a and Il17f and their receptors Il17rc and their effect on the IL6/STAT3 pathway in CCl4-induced liver fibrosis in rats. A single dose of BM-MSCs was administered to the group with induced liver fibrosis, and the genes and proteins of interest were evaluated along six weeks after treatment. Our results showed a significant downregulation of Il17a, Il17ra, il17f and Il17rc genes. In accordance, BM-MSCs administration declined IL17, IL2 and IL6 serum proteins and downregulated IL17A and IL17RA proteins in liver tissue. Interestingly, BM-MSCs downregulated both Stat3 mRNA expression and p-STAT3, while Stat5a gene was downregulated and p-STAT5 protein was elevated. Also P-SMAD3 and TGFβR2 proteins were downregulated in response to BM-MSCs treatment. Collectively, we suggest that BM-MSCs might play an immunomodulatory role in the treatment of liver fibrosis through downregulation of IL17A affecting IL6/STAT3 signaling pathway.

Citing Articles

Forskolin improves experimental autoimmune encephalomyelitis in mice probably by inhibiting the calcium and the IL-17-STEAP4 signaling pathway.

Yu Q, Li M, Anayyat U, Zhou C, Nie S, Yang H Heliyon. 2024; 10(16):e36063.

PMID: 39229522 PMC: 11369507. DOI: 10.1016/j.heliyon.2024.e36063.

A Novel Bifunctional Fusion Protein (Anti-IL-17A-sST2) Protects against Acute Liver Failure, Modulating the TLR4/MyD88 Pathway and NLRP3 Inflammasome Activation.

Bai Y, Zhou R, Xie X, Zhu A, Nan Y, Wu T Biomedicines. 2024; 12(5).

PMID: 38791080 PMC: 11117730. DOI: 10.3390/biomedicines12051118.

Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice.

Hu J, Li S, Zhong X, Wei Y, Sun Q, Zhong L Heliyon. 2024; 10(3):e25460.

PMID: 38356602 PMC: 10864966. DOI: 10.1016/j.heliyon.2024.e25460.

Comparative Histological Study of Therapeutic Effect of Mesenchymal Stem Cells versus Mesenchymal Stem Cells Co-Cultured with Liver Tissue on Carbon Tetrachloride-Induced Hepatotoxicity in Adult Male Albino Rats.

Salem B, Elkaliny H, El-Hafez A, Sarhan N J Microsc Ultrastruct. 2024; 11(4):225-236.

PMID: 38213650 PMC: 10779448. DOI: 10.4103/jmau.jmau_62_21.

Mesenchymal Stem Cells Treatment Aggravates Tumor Growth Regardless Its Route of Administration: An In vivo Study.

Mostafa A, Mohamed Abdelsalam S, S Sabbah W, Mekawey D Asian Pac J Cancer Prev. 2022; 23(10):3309-3315.

PMID: 36308353 PMC: 9924341. DOI: 10.31557/APJCP.2022.23.10.3309.

References

Zhang H, Bernuzzi F, Lleo A, Ma X, Invernizzi P . Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators Inflamm. 2015; 2015:436450. PMC: 4471389. DOI: 10.1155/2015/436450. View

Friedman S . Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol. 2005; 1(2):98-105. DOI: 10.1038/ncpgasthep0055. View

Liu Y, Liu H, Meyer C, Li J, Nadalin S, Konigsrainer A . Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem. 2013; 288(42):30708-30719. PMC: 3798541. DOI: 10.1074/jbc.M113.478685. View

Gao B . Cytokines, STATs and liver disease. Cell Mol Immunol. 2005; 2(2):92-100. View

Jang Y, Kim Y, Baik S, Kim M, Eom Y, Cho M . Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int. 2013; 34(1):33-41. DOI: 10.1111/liv.12218. View

Fabregat I, Moreno-Caceres J, Sanchez A, Dooley S, Dewidar B, Giannelli G . TGF-β signalling and liver disease. FEBS J. 2016; 283(12):2219-32. DOI: 10.1111/febs.13665. View

Baik M, Yu J, Hennighausen L . Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism. Ann N Y Acad Sci. 2011; 1229:29-37. PMC: 3427656. DOI: 10.1111/j.1749-6632.2011.06100.x. View

Jang Y, Kim M, Cho M, Baik S, Cho Y, Kwon S . Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. BMC Gastroenterol. 2014; 14:198. PMC: 4251876. DOI: 10.1186/s12876-014-0198-6. View

OReilly S, Ciechomska M, Cant R, van Laar J . Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem. 2014; 289(14):9952-60. PMC: 3975039. DOI: 10.1074/jbc.M113.545822. View

10.

Jiang J, Mikami K, Venugopal S, Li Y, Torok N . Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol. 2009; 51(1):139-48. PMC: 2765371. DOI: 10.1016/j.jhep.2009.03.024. View

11.

Zhang W, Niu M, Yan K, Zhai X, Zhou Q, Zhang L . Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. Int J Biochem Cell Biol. 2013; 45(3):736-44. DOI: 10.1016/j.biocel.2012.12.019. View

12.

Wang H, Lafdil F, Kong X, Gao B . Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011; 7(5):536-50. PMC: 3088876. DOI: 10.7150/ijbs.7.536. View

13.

Li D, Fan J, He X, Zhang X, Zhang Z, Zeng Z . Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats. Int J Clin Exp Pathol. 2015; 8(1):11-24. PMC: 4348921. View

14.

Kagan P, Sultan M, Tachlytski I, Safran M, Ben-Ari Z . Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS One. 2017; 12(5):e0176173. PMC: 5417441. DOI: 10.1371/journal.pone.0176173. View

15.

Dooley S, Ten Dijke P . TGF-β in progression of liver disease. Cell Tissue Res. 2011; 347(1):245-56. PMC: 3250614. DOI: 10.1007/s00441-011-1246-y. View

16.

Lagasse E, CONNORS H, Reitsma M, Dohse M, Osborne L, Wang X . Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000; 6(11):1229-34. DOI: 10.1038/81326. View

17.

Hammad L, Abdelraouf S, Hassanein F, Mohamed W, Schaalan M . Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?. J Immunotoxicol. 2013; 10(4):380-6. DOI: 10.3109/1547691X.2012.758198. View

18.

Pinheiro D, Leiros L, Dau J, Stumbo A, Thole A, Cortez E . Cytokines, hepatic cell profiling and cell interactions during bone marrow cell therapy for liver fibrosis in cholestatic mice. PLoS One. 2017; 12(11):e0187970. PMC: 5703547. DOI: 10.1371/journal.pone.0187970. View

19.

Soleimani M, Nadri S . A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009; 4(1):102-6. DOI: 10.1038/nprot.2008.221. View

20.

Liu Y, Zou X, Chai Y, Yao Y . Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014; 10(5):520-9. PMC: 4046879. DOI: 10.7150/ijbs.8879. View